India Reports 83 Deaths in 24 Hours

In India, in the last 24 hours, 1,260 new coronavirus cases and 83 deaths have been reported. The new fatalities increased the death toll to 5,21,264.

In India, in the last 24 hours, 1,260 new coronavirus cases and 83 deaths have been reported. The new fatalities increased the nationwide death toll to 5,21,264.

Amid a continuous downward trend, India's active caseload has further declined to 13,445, constituting 0.03 per cent of the country's total positive cases.

Omicron Variant of COVID-19
Omicron variant is a mutated strain of coronavirus (SARS-CoV-2) with faster transmissibility and enhanced virulence compared to the original COVID-19 virus.

‘A total of 1,404 patients have recovered in the last 24 hours, taking the cumulative tally to 4,24,92,326. The country's recovery rate stands at 98.76 per cent.’

Also in the same period, a total of 5,28,021 tests were conducted across the country, increasing the overall to 79.02 crore.

While the weekly positivity rate stood at 0.23 per cent, the daily positivity rate was recorded at 0.24 per cent.

As of Saturday morning, India's Covid-19 vaccination coverage exceeded 184.52 crore. This was achieved through 2,20,93,346 sessions.

Green Fungus or Aspergillosis and COVID-19 Infection
Green fungus or Aspergillosis is caused by a common mold, which exists both indoors and outdoors. Every day, people inhale Aspergillus spores, but it isn't harmful. However, it affects people who have a weak immune system. If the infection is left untreated, it can cause pneumonia.

Over 1.81 crore adolescents have been administered with the first dose of a Covid-19 vaccine since the beginning of the inoculation drive for the 12 to 14 age group.

Source-IANS

COVID-19 Antiviral Drug Offers a Better Payoff for Most Symptoms
An analysis of patient-reported data on the investigational COVID-19 antiviral drug molnupiravir shows its role in COVID-19 treatment.

Convalescent Plasma to be Effective COVID-19 Therapy: Study
Plasma from patients who recovered from COVID-19 and whose blood contains antibodies against SARS-CoV-2 is an effective and safe option as an early therapy.